LEAD PROGRAM
TDOX: TARGETED DOXORUBICIN
A cytosolic-release anthracycline conjugate engineered to enhance the therapeutic delivery of doxorubicin, particularly in tumors where multidrug resistance or cardiotoxicity pose significant challenges. TDOX conjugates doxorubicin to the XELCIS XB nanoparticle via the Z-Link self-immolative linker, enabling transport into resistant tumor cells and subsequent release in the cytosol upon glutathione activation. This represents the primary development initiative of the XELCIS XB platform.
SCROLL
WHY TDOX
A Proven Cytotoxic, Limited by Delivery, Not Biology
Doxorubicin is widely recognized as one of the most effective cytotoxic agents in oncology, utilized across numerous solid and hematologic malignancies. Its therapeutic benefit is limited by two well-documented challenges: multidrug resistance, whereby efflux pumps restrict intracellular drug accumulation in tumor cells, and cumulative toxicity, particularly cardiotoxicity, which restricts the total permissible dose over a patient's lifetime. The proposed advancement does not involve a new anthracycline; rather, it entails an improved delivery mechanism for the existing agent. This mechanism aims to facilitate the entry of doxorubicin into resistant cells and enable its release within the cytosol, thereby dissociating therapeutic efficacy from the oxidative and mitochondrial damage responsible for cardiotoxicity.
Doxorubicin Challenges Today
Multi-Drug Resistance
ATP-dependent efflux transporters, including MRP1 (ABCC1), pump doxorubicin out of tumor cells, lowering intracellular concentration below the cytotoxic threshold. This resistance is often enriched after prior chemotherapy, exactly the relapsed and refractory setting where new options are most needed.
Systemic Toxicity
Doxorubicin's cardiac damage is cumulative and caps the lifetime dose. As a chemotherapy drug delivered throughout the body, it also causes broader side effects when it reaches healthy tissue. More selective delivery into tumor cells is designed to improve that trade-off.
Current Limitations
Existing reformulations address only a portion of the issue. Liposomal doxorubicin, such as Doxill®, modifies biodistribution and reduces certain toxicities; however, it relies solely on passive accumulation and does not directly address efflux-mediated resistance, nor does it provide a specific mechanism for cytosolic drug release that ensures deep cytosolic delivery. The persistent unmet need is an active mechanism that facilitates intracellular uptake, internalization into resistant cells, and release of the therapeutic payload within the cytosol through a precisely defined intracellular trigger.
HOW TDOX WORKS
TDOX is a conjugate comprising doxorubicin covalently linked to the XELCIS XB platform via the Z-Link self-immolative linker. It functions as a conjugate rather than a passive liposomal carrier, with the payload being attached rather than encapsulated. The linker is engineered to maintain doxorubicin stability in circulation and to cleave upon entering the reducing, glutathione-rich environment of the tumor-cell cytosol. By internalizing the drug as a nanoparticle conjugate and releasing it exclusively after cytosolic entry, TDOX aims to minimize susceptibility to MRP1-mediated efflux, which targets free drug at the membrane. Consequently, more drug is delivered inside cells that would otherwise expel free doxorubicin.
Preferential Tumor Cell Uptake
Delivered as a nanoparticle conjugate, the drug penetrates resistant cells that would otherwise expel free doxorubicin. In a resistant tumor model, TDOX showed fourteen-fold higher uptake than Doxill®.
Reaches the Cytosol
pH-responsive chemistry facilitates the release of the drug from internal compartments into the cytosol, the cellular region where it exerts its function, rather than being confined and degraded.
Triggered Release
The Z-Link linker is engineered to maintain drug stability in the bloodstream and release it exclusively within the cell in response to glutathione, thereby concentrating its activity within the tumor environment.
PRECLINICAL EVIDENCE
Greater Potency and Uptake in a Resistant Model, With a Cardiac Safety Margin
9.5x
greater tumor-cell killing than Doxill® (3D spheroid resistant-tumor model)
14x
greater uptake into resistant tumor cells than Doxil®
~5x
wider heart-cell safety margin than free doxorubicin (in vitro)
~10%
endosomal escape to the cytosol, versus about 1 to 2% for published RNA-delivery lipid nanoparticles
Data generated in vitro. Potency and uptake in the H69AR multidrug-resistant model (MRP1/ABCC1-overexpressing); cardiac readouts in H9c2 cardiomyoblasts. Results are preclinical and may not predict clinical outcomes. Comparative in vivo cardiac safety is part of the planned IND-enabling program. These are not clinical cardioprotection claims.
In a multidrug-resistant 3D spheroid model, TDOX delivered substantially more drug into cells and produced correspondingly greater cytotoxicity than the passive liposomal comparator. In cardiomyocytes, TDOX showed an estimated IC50 of at least 10 uM, versus roughly 1.8 to 2.0 uM for free doxorubicin, an approximately 5-fold margin, supported by lower oxidative stress and preserved mitochondrial function. Together, these results suggest TDOX decouples anti-tumor potency from the oxidative and mitochondrial damage that drives anthracycline cardiotoxicity.
DEVELOPMENT PATH
A Broad Phase 1 With a Defined Lead Expansion
The clinical strategy pairs a broad Phase 1 entry with a defined lead expansion. Initial development focuses on advanced solid tumors where prior anthracycline exposure, multidrug-resistance biology, or cardiac risk limits standard doxorubicin. An open-label dose-escalation entry supports safety, PK, and cardiac-safety assessment across a diverse population.
Lead Indication
Platinum-Resistant, Recurrent Ovarian Cancer. Liposomal doxorubicin is already an established standard in this setting, giving TDOX a defined marketed comparator and a clean 505(b)(2) reference. MDR efflux biology is clinically relevant here, and the setting offers a tractable readout in a population with high unmet need and poor prognosis after platinum failure. The 505(b)(2) route and trial design are regulatory hypotheses to be confirmed through FDA interaction.
Additional Expansion Opportunities
Triple-negative breast cancer, relapsed or refractory small cell lung cancer (a natural fit given the SCLC-derived resistance model used in testing), and soft-tissue sarcomas, where doxorubicin is standard first-line and cardiotoxicity caps cumulative dosing. Each is a development hypothesis, conditional on in vivo and clinical data.
Cardiac-Risk Populations
A distinct, cross-indication opportunity is treating patients currently excluded from anthracycline therapy due to cardiac risk: those near cumulative-dose limits, with cardiac history, elderly patients, or childhood-cancer survivors needing re-treatment. If the in vitro cardiac margin translates in vivo and clinically, TDOX could expand the eligible population, a differentiating use gated on cardiac-safety confirmation.
The Lead Program of the XELCIS XB Platform
As the primary lead for the single payload, a favorable TDOX outcome would do more than advance a single asset. It would substantiate the fundamental XB intracellular-delivery framework, encompassing cellular uptake, endosomal escape, and Z-Link-mediated cytosolic release, thereby helping mitigate risks associated with the dual-payload combination initiatives that derive from it. Currently, in vivo efficacy and comparative cardiac-safety assessments are the immediate, seed-funded activities in progress.